Micha Breakstone, PhD
CEO & Co-founder
Presently, neurological evaluation is highly subjective, non-sensitive, and dependent on manual examination of symptoms, posing a significant challenge for timely diagnosis, patient monitoring, drug development, and precision care.
We are currently conducting research on novel biomarkers for several neurological disorders.
We are looking to partner with pharmaceutical and biotech companies, academic research institutions, clinical centers, patient advocacy groups, and other organizations promoting solutions for treatment of neurodegenerative diseases.